T and B lymphocytes in the cerebrospinal fluid of various neurological diseases

1978 ◽  
Vol 219 (3) ◽  
pp. 185-197 ◽  
Author(s):  
U. Traugott
Keyword(s):  
Cerebrospinal Fluid ◽  
B Lymphocytes ◽  
Neurological Diseases ◽  
T And B Lymphocytes

The proliferation rate of T and B lymphocytes in cerebrospinal fluid

1991 ◽  
Vol 238 (1) ◽  
pp. 27-30 ◽  
Author(s):  
R. S. Thomas ◽  
W. Beuche ◽  
K. Felgenhauer
Keyword(s):  
Cerebrospinal Fluid ◽  
B Lymphocytes ◽  
Proliferation Rate ◽  
T And B Lymphocytes

Relationship among T- and B-lymphocytes of the peripheral blood and thyroid tissue in patients with Graves' disease

2019 ◽  
Author(s):  
Margarita A Dudina ◽  
Andrey A Savchenko ◽  
Sergey A Dogadin ◽  
Alexandr G Borisov ◽  
Igor V Kudryavcev ◽  
...  
Keyword(s):  
B Lymphocytes ◽  
Peripheral Blood ◽  
Thyroid Tissue ◽  
T And B Lymphocytes ◽  
Graves Disease

scholarly journals Transplantable progenitors of natural killer cells are distinct from those of T and B lymphocytes.

1986 ◽  
Vol 83 (10) ◽  
pp. 3427-3431 ◽  
Author(s):  
J. Hackett ◽  
G. C. Bosma ◽  
M. J. Bosma ◽  
M. Bennett ◽  
V. Kumar
Keyword(s):  
Natural Killer Cells ◽  
Natural Killer ◽  
B Lymphocytes ◽  
T And B Lymphocytes ◽  
Killer Cells

scholarly journals Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients

2021 ◽  
Vol 11 (3) ◽  
pp. 296
Author(s):  
Lars Hendrik Müschen ◽  
Alma Osmanovic ◽  
Camilla Binz ◽  
Konstantin F. Jendretzky ◽  
Gresa Ranxha ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Spinal Muscular Atrophy ◽  
Total Protein ◽  
Antisense Oligonucleotide ◽  
Muscular Atrophy ◽  
Neurological Diseases ◽  
Clinical Signs ◽  
Central Nervous System Disease ◽  
Oligoclonal Bands ◽  
System Disease

Approval of nusinersen, an intrathecally administered antisense oligonucleotide, for the treatment of 5q-spinal muscular atrophy (SMA) marked the beginning of a new therapeutic era in neurological diseases. Changes in routine cerebrospinal fluid (CSF) parameters under nusinersen have only recently been described in adult SMA patients. We aimed to explore these findings in a real-world setting and to identify clinical and procedure-associated features that might impact CSF parameters. Routinely collected CSF parameters (leukocyte count, lactate, total protein, CSF/serum albumin quotient (QAlbumin), oligoclonal bands) of 28 adult SMA patients were examined for up to 22 months of nusinersen treatment. Total protein and QAlbumin values significantly increased in the first 10 months, independent of the administration procedure. By month 14, no further increases were detected. Two patients developed transient pleocytosis. In two cases, positive oligoclonal bands were found in the beginning and in four patients throughout the whole observation period. No clinical signs of inflammatory central nervous system disease were apparent. Our data confirm elevated CSF total protein and QAlbumin during nusinersen treatment. These alterations may be caused by both repeated lumbar punctures and the interval between procedures rather than by the medication itself. Generally, there were no severe alterations of CSF routine parameters. These results further underline the safety of nusinersen therapy.

scholarly journals Cerebrospinal Fluid Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1210
Author(s):  
Júlia Costa ◽  
Marta Gromicho ◽  
Ana Pronto-Laborinho ◽  
Conceição Almeida ◽  
Ricardo A. Gomes ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Motor Neurons ◽  
Neurological Diseases ◽  
Disease Diagnosis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Progression Rate ◽  
Therapeutic Trials ◽  
Als Patients ◽  
Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative neuromuscular disease that affects motor neurons controlling voluntary muscles. Survival is usually 2–5 years after onset, and death occurs due to respiratory failure. The identification of biomarkers would be very useful to help in disease diagnosis and for patient stratification based on, e.g., progression rate, with implications in therapeutic trials. Neurofilaments constitute already-promising markers for ALS and, recently, chitinases have emerged as novel marker targets for the disease. Here, we investigated cerebrospinal fluid (CSF) chitinases as potential markers for ALS. Chitotriosidase (CHIT1), chitinase-3-like protein 1 (CHI3L1), chitinase-3-like protein 2 (CHI3L2) and the benchmark marker phosphoneurofilament heavy chain (pNFH) were quantified by an enzyme-linked immunosorbent assay (ELISA) from the CSF of 34 ALS patients and 24 control patients with other neurological diseases. CSF was also analyzed by UHPLC-mass spectrometry. All three chitinases, as well as pNFH, were found to correlate with disease progression rate. Furthermore, CHIT1 was elevated in ALS patients with high diagnostic performance, as was pNFH. On the other hand, CHIT1 correlated with forced vital capacity (FVC). The three chitinases correlated with pNFH, indicating a relation between degeneration and neuroinflammation. In conclusion, our results supported the value of CHIT1 as a diagnostic and progression rate biomarker, and its potential as respiratory function marker. The results opened novel perspectives to explore chitinases as biomarkers and their functional relevance in ALS.

Monoclonal antibodies that distinguish bovine T and B lymphocytes

1985 ◽  
Vol 9 (1) ◽  
pp. 87-102 ◽  
Author(s):  
Harris A. Lewin ◽  
William C. Davis ◽  
Domenico Bernoco
Keyword(s):  
Monoclonal Antibodies ◽  
B Lymphocytes ◽  
T And B Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document